Towards Healthcare
North America Cell and Gene Therapy Market to Rise 24.01% CAGR till 2034

North America Cell and Gene Therapy Market Advanced Therapies Drives Rapid Growth

According to forecasts, the North America cell and gene therapy market will grow from USD 9.19 billion in 2024 to USD 79.01 billion by 2034, with an expected CAGR of 24.01%. The North America cell and gene therapy market is growing due to the rising demand for highly specific therapeutics for genetic disorders.

Content

  • Last Updated: 13 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The North America cell and gene therapy market in 2025 is valued at USD 11.34 billion and is projected to climb to USD 79.01 billion by 2034, with a CAGR of 24.01% over the forecast period.

The U.S. is currently leading the North America cell and gene therapy market due to government support and initiatives taken by organizations such as the FDA.

Some key players include Novartis AG, Bluebird Bio, CRISPR Therapeutics, Bristol Myers Squibb, etc.

Key trends include rising demand for personalized medicine and clinical research for developing cell and gene therapies for rare diseases.

National Institutes of Health, FDA, WHO, CDC.
Any Questions